The demand for biologics is driven by an increase in regulatory approvals at different stages of clinical trials and commercial studies, and this demand is anticipated to fuel market expansion throughout the forecast period. The U.S. Food and Drug Administration (FDA) approved Lunsumio for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) on December 22, 2022, according to a statement from the pharmaceutical company Genentech. A novel class of fixed-duration cancer immunotherapy is represented by Lunsumio, a bispecific antibody that engages CD20xCD3 T-cells.
The global Biologics Outsourcing Market is anticipated to reach US$ 19.67 billion in 2023 and is anticipated to grow at a CAGR of 12.9% from 2023 to 2030.
Key Companies in the Biologics Outsourcing Industry:
1. Thermo Fisher Scientific Inc.: Established in 1956. Headquarters in the United States. Thermo Fisher Scientific sells reagents for life sciences, laboratory supplies, and equipment for diagnostics. As of mid-2023, the company works through four segments: analytical technologies (16% of sales); speciality diagnostic products (10% of revenue); life science solutions (24% of revenue); and lab goods and services, which includes CRO services (54% of revenue).
2. Fujifilm Diosynth Biotechnologies: Created in 1994. United States headquarters. Manufacturer of pharmaceutical goods with the mission to improve the development of tomorrow's medicines through technical leadership in cell culture, biologics, microbial fermentation, and cell and gene therapy. The business specialises in providing comprehensive pharmaceutical manufacturing solutions, from pre-clinical research and process development to commercial cGMP production, assisting clients in advancing more quickly, enhancing capacities, streamlining procedures, and fostering innovation. In 2022, FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) stated that it had successfully paid USD 100 million for Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to sell it a dedicated cell therapy production plant. The
3. Curia Global, Inc.: Founded in 1991. United States headquarters. a company that offers manufacturing and contract research services with the goal of enhancing patient outcomes and overall quality of life. The business helps the pharmaceutical and biotechnology sectors find answers for drug discovery, drug development, analytical services, and manufacturing problems so they may address difficult scientific problems and improve the lives of patients. The privately held formulation and fill-finish company Integrity Bio, Inc., with headquarters in Camarillo, California, was acquired by Curia, a top contract research, development, and manufacturing organisation, in 2021.
4. Bionova Scientific, Inc.: Established in 2014. United States headquarters.Owner of a contract development and manufacturing organisation (CDMO) that offers services for developing biopharmaceutical processes. The business oversees all phases of biologics development and production, including early-stage research material creation, process development, and contract manufacturing services. This enables biologic drug development companies to ensure the quicker and more effective release of life-changing therapies. Bionova Scientific, a biopharmaceutical CDMO established in the US, was purchased by Asahi Kasei Medical.
5. Boehringer Ingelheim International GmbH: Established in 1969. Headquarters in Germany. Boehringer Ingelheim Pharmaceuticals' Rosemer Operations. The business offers standard and client-specific polymers for use in pharmaceutical formulations and medical applications. 10 brands of pharmaceuticals. Brands like Antistax®, Bisolvon®, Buscopan®, Dulcolax®, Eve®, Mucoangin®, Mucosolvan®, Pharmaton®, Thomapyrin®, and Zantac® are among those offered by the Consumer Health Care division. These medications work effectively for treating colds and coughs, sore throats, generalised discomfort, gastrointestinal issues, and deficiencies in vitamins and minerals that are essential for both physical and mental health. In 2022, Boehringer Ingelheim announced that it had signed a legally binding contract to acquire all of the outstanding shares of NBE-Therapeutics, a privately held, clinical-stage Swiss biotechnology company that specialises in developing antibody-drug conjugates and targeted cancer therapies based on its immune stimulatory iADCTM platform.
6. STC Biologics: Founded in 2009. Headquarters in the United States. Owner of a Newton, Massachusetts-based biotech business. The company specialises in drug development from target selection to IND/CTA filling and BLA/MAA, biologics process development, analytics-driven process development, and biosimilar development. It focuses on the development of biologic pharmaceuticals with an emphasis on biosimilars. Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, in 2020 announces the execution of an agreement with STC Biologics, Inc. ("STC") for GMP manufacturing of TZLS-501, an anti-IL-6 receptor (anti-IL-6R) monoclonal antibody (mAb) acquired from Novimmune in 2017, currently in agreement with Bristol Myers Squibb (BMS).
7. Abbvie Inc.: Headquarters in the United States. Pharmaceutical company AbbVie has a significant presence in oncology and immunology. Humira, the company's best-selling medication, accounts for about half of its current earnings. Early in 2013, the company was separated from Abbott. Allergan's latest acquisition has included a number of new cosmetic and women's health medications. Complete transformational acquisition of Allergan by AbbVie
*Definition: Biologics are a more complex class of medicines to manufacture, package, store, and distribute than their chemical counterparts.
